View Our Clinical Trials

office@woendo.com

(407) 480-4830

1510 Citrus Medical Ct
Ocoee, FL 34761

Clinical Trials

Current Areas of Disease Research :

  • Type 2 Diabetes & Obesity
  • Chronic Kidney Disease
  • Obesity
  • Hypothyroidism

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Active – Recruiting:

___________________________________________________________________________________________________________________________________________________________________________________________________________________

BaxDuo Arctic / D6972C00003

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone.

  • Condition: Chorionic Kidney Disease with Proteinuria
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
  • Study Length: 24-months
  • Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Avanti / M21-341

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

  • Condition: Hypothyroidism
  • Status: Active – Recruiting
  • Sponsor: AbbVie
  • Type of Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
  • Study Length: 81 Weeks
  • Target Age/Sex: 18 Years to 75 Years   (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06345339
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

ReCET / 898

  • Condition: Type II Diabetes
  • Endogenex raises $88M for Recet trial in T2D | BioWorldStatus: Active – Recruiting
  • Sponsor: Endogenex
  • Type of Study: A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes.
  • Study Length: 52 Weeks
  • Target Age/Sex: 18 Years to 70 Years   (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Check Procedure Video: https://www.endogenex.com/recet/
  • To check eligibility criteria please visit: https://clinicaltrials.gov/study/NCT06267391
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Active – Closed Enrollment

___________________________________________________________________________________________________________________________________________________________________________________________________________________

ACHIEVE-4 / J2A-MC-GZGS

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Eli Lilly
  • Type of Study: A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk.
  • Study Length: 104 weeks
  • Target Age/Sex: 18 Years and older, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05803421
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

ACHIEVE-3 / J2A-MC-GZGU

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin.

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Eli Lilly
  • Type of Study: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
  • Study Length: 52 Weeks
  • Target Age/Sex: 18 Years and older   (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06045221
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

ACHIEVE-1 / J2A-MC-GZGT

Effect of LY3502970 Compared with Placebo in Participants with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Eli Lilly
  • Type of Study: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 compared with Placebo in Adult Participants with Type 2 Diabetes and inadequate Glycemic Control with Diet and Exercise Alone.
  • Study Length: 42 weeks
  • Target Age/Sex: 18 Years and older, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

SYNCHRONIZE™-2 / 1404-0041

A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight.

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Boehringer Ingelheim
  • Type of Study: A Phase 3, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.
  • Study Length: 76weeks
  • Target Age/Sex: 18 Years and older, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06066528
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

REIMAGINE 2 / NN9388-4896

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Novo Nordisk
  • Type of Study: a Phase 3 study to measure the efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
  • Study Length: 68 Weeks
  • Target Age/Sex: 18 Years and older (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06065540
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

REIMAGINE 4 / NN9388-4894

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Novo Nordisk
  • Type of Study: a Phase 3 study to measure the efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
  • Study Length: 68 Weeks
  • Target Age/Sex: 18 Years and older (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06221969
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Revitalize 1 / C-00044Revitalize 1

Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy

  • Condition: Type 2 Diabetes and Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Fractyl
  • Type of Study: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
  • Study Length: 24 Weeks
  • Target Age/Sex: 21 Years to 70 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Confidence / 21839

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

  • Condition: Chorionic Kidney Disease with Proteinuria
  • Status: Active, Closed Enrollment.
  • Sponsor: Bayer
  • Type of Study: A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.
  • Study Length: 30 Weeks
  • Target Age/Sex: 18 Years and older (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05254002
  • To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

___________________________________________________________________________________________________________________________________________________________________________________________________________________

SYNCHRONIZE™-1 / 1404-0038

Efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.

  • Condition: Obesity
  • Status: Active, Closed Enrollment.
  • Sponsor: Boehringer Ingelheim
  • Type of Study: A Phase III, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
  • Study Length: 76 weeks
  • Target Age/Sex: 18 Years and older, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Link: https://classic.clinicaltrials.gov/ct2/show/NCT06066515

___________________________________________________________________________________________________________________________________________________________________________________________________________________

STABILIZE-CKD –  D9488C0001

Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia

  • Condition: Chorionic Kidney Disease with Proteinuria
  • Status: Closed – Closed Enrollment
  • Sponsor: AstraZeneca
  • Type of Study:  A Phase 3, International, Randomized, Double-Blind.
  • Study Title: Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia
  • Study Length: 28 months
  • Target Age/Sex: Over 18 years, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Link: https://clinicaltrials.gov/ct2/show/NCT05056727

___________________________________________________________________________________________________________________________________________________________________________________________________________________

QWINT-3 – I8H-MC-BDCU

The QWINT-3 Study is testing an investigational basal insulin taken once weekly compared with basal insulin that is taken daily.

  • Condition: Type 2 Diabetes
  • Sponsor: Eli Lilly
  • Status: Closed – Closed Enrollment.
  • Type of Study: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
  • Study Length: 86 weeks
  • Target Age/Sex: 18 Years and older, Male and Female
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Completed Trials:

1.NCT Number: NCT00698230. Study Name: . Sponsor: Incyte Corporation. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2009.

2.NCT Number: NCT00707993. Study Name: . Sponsor: Takeda. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2010.

3.NCT Number:  NCT00751842. Study Name: DIAPREVENT. Sponsor: Diamyd Therapeutics AB. Role: Sub- Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2012. Completed Date: 2012.

4.NCT Number: NCT01989754. Study Name: CANVAS. Sponsor: Janssen Research & Development, LLC. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2017.

5.NCT Number: NCT00789737. Study Name: . Sponsor: Daiichi Sankyo, Inc. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2009. Completed Date: 2011.

6.NCT Number: NCT01018173. Study Name: . Sponsor: Roche. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2010. Completed Date: 2011.

7.NCT Number: NCT01499082. Study Name: Edition I. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

8.NCT Number: NCT02855684. Study Name: Edition AP. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

9.NCT Number: NCT01995734. Study Name: ACCESS. Sponsor: Novartis Pharmaceuticals. Role: Principal Investigator. Condition I: Acromegaly. Start date: 2013. Completed Date: 2015.

10.NCT Number: NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

11.NCT Number:  NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

12.NCT Number: NCT02320721. Study Name: SENIOR. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

13.NCT Number: NCT02294474. Study Name: SORELLA2. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

14.NCT Number: NCT02967224. Study Name: (Reach-Control). Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2017.

15.NCT Number: NCT02642159. Study Name: ODYSSEY DM-Dyslipidemia. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

16.NCT Number: NCT02738151. Study Name: BRIGHT. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

17.NCT Number: NCT02688933. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

18.NCT Number: NCT03211858. Study Name: GEMELLI1. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2019.

19.NCT Number: NCT03066830. Study Name: SOTA-SU. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

20.NCT Number: NCT03242018. Study Name: SOTA-CKD4. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

21.NCT Number: NCT03242252. Study Name: SOTA-CKD3. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

22.NCT Number: NCT03332771. Study Name: SOTA-GLIM. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

23.NCT Number: NCT03449199. Study Name: . Sponsor: Teijin America, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2019.

24.NCT Number: NCT03518034. Study Name: TRAVERSE. Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2018. Completed Date: 2023.

25.NCT Number: NCT03351478. Study Name: SOTA-EMPA. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

26.NCT Number: NCT02092467. Study Name: . Sponsor: Pfizer. Role: Principal Investigator. Condition I: RHEUMATOID ARTHRITIS. Start date: 2014. Completed Date: 2020.

27.NCT Number: NCT03285594. Study Name: SOTA-INS. Sponsor: Lexicon Pharmaceuticals/ Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

28.NCT Number: NCT03767543. Study Name: DIVERSITY. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

29.NCT Number: NCT03874715. Study Name: GEMELLI X. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

30.NCT Number:  NCT03895203. Study Name: BE OPTIMAL. Sponsor: UCB Biopharma SRL. Role: Principal Investigator. Condition I: Psoriatic Arthritis. Start date: 2019. Completed Date: 2022.

31.NCT Number: NCT03071692. Study Name: PROMINENT. Sponsor: Kowa Research Institute, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2022.

32.NCT Number: NCT03990363. Study Name: SAPPHIRE. Sponsor: AstraZeneca. Role: Principal Investigator. Condition I: Chronic Kidney Disease. Start date: 2019. Completed Date: 2022.

33.NCT Number: NCT04064411. Study Name: The wearABLe Study. Sponsor: Radius Health, Inc. Role: Principal Investigator. Condition I: Osteoporosis. Start date: 2019. Completed Date: 2021.

34.NCT Number: NCT04274894. Study Name: . Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2020. Completed Date: 2021.

35.NCT Number: NCT04854512. Study Name: DREAM-T2D. Sponsor: Anji Pharma. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2023.

36.NCT Number: NCT04419467. Study Name: . Sponsor: CSL Behring. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2020. Completed Date: 2022.

37.NCT Number: NCT04657003. Study Name: SURMOUNT-2. Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2021. Completed Date: 2023.

NCT Number: NCT05182840. Study Name: MANOUVER. Sponsor: Boehringer Ingelheim. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2022. Completed Date: